Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

BACKGROUND/AIMS: Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance may enhance dose and treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, Hiroyuki, Dirks, Nathanael L., Rosario, Maria, Hori, Tetsuharu, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873400/
https://www.ncbi.nlm.nih.gov/pubmed/32635680
http://dx.doi.org/10.5217/ir.2019.09167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873400/
https://www.ncbi.nlm.nih.gov/pubmed/32635680
http://dx.doi.org/10.5217/ir.2019.09167

Ejemplares similares